AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.31-3.63 (-1.06%) ▼|ABBV288.39+5.71 (+2.02%) ▲|ABT102.70-1.36 (-1.31%) ▼|ACN239.21+2.28 (+0.96%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.62+0.59 (+0.32%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.41+2.00 (+0.63%) ▲|BA190.39-1.03 (-0.54%) ▼|BAC50.66+0.27 (+0.54%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.55+3.95 (+0.35%) ▲|BMY61.72+2.89 (+4.90%) ▲|BNY144.26+1.82 (+1.27%) ▲|BRK-B540.18+7.95 (+1.49%) ▲|C122.53+0.84 (+0.69%) ▲|CAT725.47-0.32 (-0.04%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.58+1.75 (+0.88%) ▲|COP145.97+0.73 (+0.50%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.44-0.01 (0.00%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.71+2.03 (+2.19%) ▲|CVX225.78+1.41 (+0.63%) ▲|DE632.54+5.54 (+0.88%) ▲|DHR224.02-0.41 (-0.18%) ▼|DIS111.66+2.07 (+1.88%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.48-0.07 (-0.04%) ▼|FDX298.76+4.98 (+1.69%) ▲|GD344.48+3.05 (+0.89%) ▲|GE299.92-11.36 (-3.65%) ▼|GEV890.50-17.94 (-1.97%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.10-5.65 (-6.83%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.99+9.21 (+1.05%) ▲|HD315.16+5.28 (+1.70%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM242.02+5.63 (+2.38%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.42+5.63 (+2.22%) ▲|JPM335.45+1.92 (+0.58%) ▲|KO93.51+0.09 (+0.09%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,284.88+44.54 (+3.59%) ▲|LMT548.87+0.64 (+0.12%) ▲|LOW198.58+2.66 (+1.36%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.52+4.12 (+0.67%) ▲|MCD246.54+3.87 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.67+1.90 (+2.05%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.44+9.43 (+5.82%) ▲|MO74.63+0.54 (+0.73%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.43+1.96 (+1.10%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.89+0.72 (+0.92%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.89+0.68 (+1.83%) ▲|NOW149.58+4.22 (+2.90%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.09+1.50 (+1.16%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG159.38+1.69 (+1.07%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.93-1.12 (-0.56%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.83+8.45 (+1.24%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
19.1 C
New York
Tuesday, October 20, 2026

Tag: physicians

newsFORsourcecompanycontentinformation1releasesmarket

BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback

June 9, 2026
Announcement no. 12

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Basel, June 8th, 2026 – Novartis will present data from 10 abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026, spanning Rhapsido®  (remibrutinib) clinical trial results and real-world evidence on patient burden and treatment experience. Highlights include two late-breaking oral presentations; the Phase III RemIND trial for Rhapsido in chronic inducible urticaria (CIndU) and extension data from the Phase IIIb REMIXED trial in chronic spontaneous urticaria (CSU).

“The Rhapsido presentations at EAACI 2026 expand our understanding of BTK inhibition across multiple immune-mediated diseases and provide evidence of its potential to make a meaningful impact for patients who continue to face significant burden and limited treatment options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “Novartis will present Rhapsido data from a long-term extension trial in chronic spontaneous urticaria, Phase III data in three types of chronic inducible urticaria, and early Phase II dose-response analysis for food allergy – together providing scientific evidence for its impact across numerous diseases.”

Abstracts accepted by EAACI include: 

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

The American Diabetes Association Announces Winners of the Innovation Challenge

NEW ORLEANS, June 6, 2026 /PRNewswire/ -- Today, from the main stage at the organization's 2026 Scientific Sessions, the American Diabetes Association® (ADA) announced...

From Bystanders to Heart Savers: MedStar Health CPR Training Event Puts Power to Save Lives in Community’s Hands

SILVER SPRING, Md., June 6, 2026 /PRNewswire/ -- MedStar Health marked CPR & AED Awareness Week with its third annual training event held at...

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

Greenberg Traurig Expands Health Care & FDA Capabilities in California with Addition of Deborah J. Rotenberg and Team

SACRAMENTO, Calif., June 5, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP continues the growth of its Health Care & FDA Practice with the...

St. Joseph’s Children’s Hospital Cancer Survivor Advocates for Children’s Health Care on Capitol Hill

TAMPA, Fla., June 5, 2026 /PRNewswire/ -- This week, 7-year-old Mikey Hartnett and his parents joined leaders from BayCare and St. Joseph's Children's Hospital...

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut. 
A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPhysicians

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers